Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
80.79B
Market cap80.79B
Price-Earnings ratio
19.40
Price-Earnings ratio19.40
Dividend yield
0.47%
Dividend yield0.47%
Average volume
740.14K
Average volume740.14K
High today
$794.73
High today$794.73
Low today
$779.65
Low today$779.65
Open price
$781.55
Open price$781.55
Volume
2.46M
Volume2.46M
52 Week high
$859.34
52 Week high$859.34
52 Week low
$541.00
52 Week low$541.00

Stock Snapshot

With a market cap of 80.79B, Regeneron(REGN) trades at $784.85. The stock has a price-to-earnings ratio of 19.40 and currently yields dividends of 0.47%.

As of 2026-09-21, Regeneron(REGN) stock has fluctuated between $779.65 and $794.73. The current price stands at $784.85, placing the stock +0.7% above today's low and -1.2% off the high.

Regeneron(REGN) shares are trading with a volume of 2.46M, against a daily average of 740.14K.

In the last year, Regeneron(REGN) shares hit a 52-week high of $859.34 and a 52-week low of $541.00.

In the last year, Regeneron(REGN) shares hit a 52-week high of $859.34 and a 52-week low of $541.00.

REGN News

TipRanks 3d
Itepekimab COPD Extension Trial Completion: What It Means for Regeneron and Sanofi

Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. The extension study “A Double-blinded Extension Study to...

Simply Wall St 3d
How Investors Are Reacting To Regeneron Pharmaceuticals Stock Trial Disclosure Lawsuits

Regeneron Pharmaceuticals is facing federal securities class action lawsuits filed in September 2026 that allege misleading disclosures about the Phase III Fian...

How Investors Are Reacting To Regeneron Pharmaceuticals Stock Trial Disclosure Lawsuits
TipRanks 5d
Regeneron’s ROXI-EVEREST Trial Puts a New Stroke Drug in the Spotlight

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals, Inc. is advancing a late-stage heart study cal...

Analyst ratings

60%

of 30 ratings
Buy
60%
Hold
33.3%
Sell
6.7%

More REGN News

Simply Wall St 6d
Is Regeneron Pharmaceuticals Still Undervalued After The Class Action Lawsuits?

Advertisement Why the Regeneron Pharmaceuticals lawsuits matter for investors Regeneron Pharmaceuticals (REGN) is under pressure after multiple law firms laun...

Is Regeneron Pharmaceuticals Still Undervalued After The Class Action Lawsuits?

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
Eli Lilly
MercadoLibre
Palo Alto Networks
UnitedHealth
Broadcom
Meta Platforms

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.